A Phase 2 Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222722

Enrollment

325

Registered

2015-01-16

Start date

2015-01-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : E

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Subject with type 2 diabetes mellitus 2)Male or female subjects aged 20 years or older at informed consent 3)Subject with urinary albumin to creatine ratio (UACR) >= 45 mg/g Cr and = 30 mL/min/1.73 m2 5)Subjects treated with angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for more than 3 months prior to treatment period

Exclusion criteria

Exclusion criteria: Type-1 diabetics 2)HbA1c (NGSP) >=8.4% 3)Secondary glucose intolerance 4)Subjects diagnosed with non-diabetic nephropathy 5)Nephrotic syndrome 6)Secondary hypertension or malignant hypertension Serum potassium level in any of the following categories: For subjects with eGFRcreat of >= 45 mL/min/1.73 m2, serum potassium level of = 5.1 mEq/L; For subjects with eGFRcreat of >= 30 mL/min/1.73 m2 and = 4.8 mEq/L

Design outcomes

Primary

Measure	Time frame
Change from baseline in urinary albumin to creatine ratio (UACR)	—

Secondary

Measure	Time frame
Transition from microalbuminuria to normoalbuminuria Change in renal function Change in serum potassium	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026